Merck & Co. Inc. share price today

(MRK)

Merck & Co. Inc. share price is $100.61 & ₹8,520.16

$100.61

▲

-1.03

(-1.01%)

Market is closed - opens 8 PM, 03 Dec 2024

View live Merck & Co. Inc. share price in Dollar and Rupees. Guide to invest in Merck & Co. Inc. from India. Also see the sentimental analysis on Indian investors investing in Merck & Co. Inc.. Get details on the Indian mutual funds that are investing in Merck & Co. Inc.. Get Analyst recommendations and forecasts along with all the Merck & Co. Inc.'s financials.

Merck & Co. Inc. share price movements

$100.48
$101.64
$100.61
0.13%
Downside
Day's Volatility :1.14%
Upside
1.01%
$94.48
$134.63
$100.61
6.09%
Downside
52 Weeks Volatility :29.82%
Upside
25.27%

Merck & Co. Inc. Returns

Period	Merck & Co. Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-13.7%	-6.2%	9.4%
6 Months	-21.83%	1.7%	16.1%
1 Year	-4.24%	11.6%	23.6%
3 Years	37.03%	12.9%	29.5%

Merck & Co. Inc. Key Statistics

in dollars & INR

Market Capitalization	$260.9B
Revenue TTM	$63.2B
EBITDA	$22.9B
Earnings Per Share (EPS)	$4.78
PE Ratio	21.26
Dividend Yield	3.19%
Profit Margin	19.23%
Quarterly Earnings Growth YOY	-0.33%
Return On Equity TTM	28.33%

How to invest in Merck & Co. Inc. from India?

It is very easy for Indian residents to invest directly in Merck & Co. Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Merck & Co. Inc. stock in both rupees (INR) and dollars (USD). Search for Merck & Co. Inc. or MRK on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Merck & Co. Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Merck & Co. Inc. shares which would translate to 0.008 fractional shares of Merck & Co. Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Merck & Co. Inc.

-14.61%

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Investment in Merck & Co. Inc. from India has reduced in the last 30 days as on Dec 3, 2024. -14.61% less purchase transactions for Merck & Co. Inc. in the last 30 days versus the previous period.

28%

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Search volume for Merck & Co. Inc. on INDmoney from India has grown in the last 30 days as on Dec 3, 2024. 28% more investors are searching Merck & Co. Inc. in the last 30 days versus the previous period.

Indian Mutual Funds that own Merck & Co. Inc.

Name	Shares Held	Change in Shares	% of Assets
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	3549	152.25	1.95%
Motilal Oswal S&P 500 Index Fund Direct Growth	21783	-1184.12	0.53%
Axis Growth Opportunities Fund Direct Growth	56526	0.00	0.35%
Axis Innovation Fund Direct Growth	2958	0.00	0.21%

Global Institutional Holdings in Merck & Co. Inc.

Vanguard Group Inc
9.88%
BlackRock Inc
8.19%
State Street Corp
4.71%
Wellington Management Company LLP
3.00%
Geode Capital Management, LLC
2.34%
FMR Inc
1.97%

Analyst Recommendation on Merck & Co. Inc.

Buy

87%Buy

12%Hold

0%Sell

Based on 31 Wall street analysts offering stock ratings for Merck & Co. Inc.(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Merck & Co. Inc.

What analysts predicted

Upside of 29.54%

Current:

$100.61

Target:

$130.33

Insights on Merck & Co. Inc.

Increasing Revenue
Merck & Co. Inc. has shown positive revenue growth over the last four quarters. Revenue increased from $14.63 billion to $16.65 billion, reflecting an average growth rate of 4.2% per quarter.
Decreasing Net Profit
Merck & Co. Inc. has experienced a decline in net profit over the last two quarters. The profit decreased from $5.45 billion to $3.15 billion, reflecting an average decrease of 42.1% per quarter.
Vs LLY
In the last 1 year, Eli Lilly And Company has given 36.9% return, outperforming this stock by 39.7%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 225.7% return, outperforming this stock by 188.5%

Merck & Co. Inc. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$42.3B	↑ 5.41%
Net Income	$6.2B	↑ 142.21%
Net Profit Margin	14.71%	↑ 8.31%

	FY19	Y/Y Change
Revenue	$46.8B	↑ 10.75%
Net Income	$9.8B	↑ 58.25%
Net Profit Margin	21.01%	↑ 6.3%

	FY20	Y/Y Change
Revenue	$41.5B	↓ 11.36%
Net Income	$7.1B	↓ 28.2%
Net Profit Margin	17.02%	↓ 3.99%

	FY21	Y/Y Change
Revenue	$48.7B	↑ 17.31%
Net Income	$13.0B	↑ 84.65%
Net Profit Margin	26.79%	↑ 9.77%

	FY22	Y/Y Change
Revenue	$59.3B	↑ 21.72%
Net Income	$14.5B	↑ 11.27%
Net Profit Margin	24.49%	↓ 2.3%

	FY23	Y/Y Change
Revenue	$60.1B	↑ 1.4%
Net Income	$365.0M	↓ 97.49%
Net Profit Margin	0.61%	↓ 23.88%

	Q2 FY23	Q/Q Change
Revenue	$15.0B	↑ 3.78%
Net Income	$-6.0B	↓ 311.8%
Net Profit Margin	-39.74%	↓ 59.21%

	Q3 FY23	Q/Q Change
Revenue	$16.0B	↑ 6.17%
Net Income	$4.7B	↓ 179.41%
Net Profit Margin	29.73%	↑ 69.47%

	Q4 FY23	Q/Q Change
Revenue	$14.6B	↓ 8.34%
Net Income	$-1.2B	↓ 125.84%
Net Profit Margin	-8.38%	↓ 38.11%

	Q1 FY24	Q/Q Change
Revenue	$15.8B	↑ 7.83%
Net Income	$4.8B	↓ 488.42%
Net Profit Margin	30.19%	↑ 38.57%

	Q2 FY24	Q/Q Change
Revenue	$16.2B	↑ 2.42%
Net Income	$5.5B	↑ 14.55%
Net Profit Margin	33.76%	↑ 3.57%

	Q3 FY24	Q/Q Change
Revenue	$16.7B	↑ 3.1%
Net Income	$3.2B	↓ 42.13%
Net Profit Margin	18.95%	↓ 14.81%

	FY18	Y/Y Change
Total Assets	$82.6B	↓ 5.96%
Total Liabilities	$55.8B	↑ 4.6%

	FY19	Y/Y Change
Total Assets	$84.4B	↑ 2.13%
Total Liabilities	$58.4B	↑ 4.74%

	FY20	Y/Y Change
Total Assets	$91.6B	↑ 8.52%
Total Liabilities	$66.2B	↑ 13.34%

	FY21	Y/Y Change
Total Assets	$105.7B	↑ 15.4%
Total Liabilities	$67.4B	↑ 1.89%

	FY22	Y/Y Change
Total Assets	$109.2B	↑ 3.28%
Total Liabilities	$63.1B	↓ 6.43%

	FY23	Y/Y Change
Total Assets	$106.7B	↓ 2.28%
Total Liabilities	$69.0B	↑ 9.41%

	Q2 FY23	Q/Q Change
Total Assets	$104.5B	↓ 3.09%
Total Liabilities	$65.7B	↑ 7.94%

	Q3 FY23	Q/Q Change
Total Assets	$106.7B	↑ 2.16%
Total Liabilities	$65.4B	↓ 0.46%

	Q4 FY23	Q/Q Change
Total Assets	$106.7B	↓ 0.05%
Total Liabilities	$69.0B	↑ 5.52%

	Q1 FY24	Q/Q Change
Total Assets	$105.8B	↓ 0.77%
Total Liabilities	$65.4B	↓ 5.24%

	Q2 FY24	Q/Q Change
Total Assets	$112.6B	↑ 6.41%
Total Liabilities	$69.0B	↑ 5.44%

	Q3 FY24	Q/Q Change
Total Assets	$117.5B	↑ 4.35%
Total Liabilities	$73.0B	↑ 5.78%

	FY18	Y/Y Change
Operating Cash Flow	$10.9B	↑ 69.41%
Investing Cash Flow	$4.3B	↑ 61.03%
Financing Cash Flow	$-13.2B	↑ 31.52%

	FY19	Y/Y Change
Operating Cash Flow	$13.4B	↑ 23.05%
Investing Cash Flow	$-2.6B	↓ 160.94%
Financing Cash Flow	$-8.9B	↓ 32.67%

	FY20	Y/Y Change
Operating Cash Flow	$10.3B	↓ 23.71%
Investing Cash Flow	$-9.4B	↑ 259.19%
Financing Cash Flow	$-2.8B	↓ 68.04%

	FY21	Y/Y Change
Operating Cash Flow	$14.1B	↑ 37.61%
Investing Cash Flow	$-16.6B	↑ 75.32%
Financing Cash Flow	$2.6B	↓ 191.56%

	FY22	Y/Y Change
Operating Cash Flow	$19.1B	↑ 35.34%
Investing Cash Flow	$-5.0B	↓ 70.04%
Financing Cash Flow	$-9.1B	↓ 451.68%

	FY23	Y/Y Change
Operating Cash Flow	$13.0B	↓ 31.89%
Investing Cash Flow	$-14.1B	↑ 183.93%
Financing Cash Flow	$-4.8B	↓ 47.25%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$3.7B	↑ 176.62%
Investing Cash Flow	$-11.4B	↑ 385.08%
Financing Cash Flow	$3.8B	↓ 282.96%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$7.7B	↑ 108.34%
Investing Cash Flow	$-334.0M	↓ 97.08%
Financing Cash Flow	$-4.3B	↓ 213.6%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$246.0M	↓ 96.81%
Investing Cash Flow	$53.0M	↓ 115.87%
Financing Cash Flow	$-2.2B	↓ 47.41%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$3.1B	↑ 1156.1%
Investing Cash Flow	$-1.4B	↓ 2696.23%
Financing Cash Flow	$-2.8B	↑ 25.35%

Merck & Co. Inc. Technicals Summary

Sell

Neutral

Buy

Merck & Co. Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Merck & Co. Inc. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Merck & Co. Inc.	-1.24%	-21.83%	-4.24%	37.03%	13.36%
Eli Lilly And Company	-0.79%	-3.94%	36.56%	224.69%	567.78%
Johnson & Johnson	-2.17%	4.74%	-2.57%	-5.0%	10.92%
Novo Nordisk A/s	-0.96%	-22.33%	7.68%	101.71%	280.83%
Abbvie Inc	-9.33%	12.11%	26.1%	49.79%	109.61%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Merck & Co. Inc.	21.26	21.26	0.07	7.75	0.28	0.11	0.03	17.58
Eli Lilly And Company	85.43	85.43	0.75	13.16	0.65	0.14	0.01	15.83
Johnson & Johnson	25.65	25.65	0.92	9.96	0.21	0.08	0.03	29.14
Novo Nordisk A/s	34.03	34.03	1.59	22.7	0.89	0.21	0.01	27.07
Abbvie Inc	63.74	63.74	0.44	10.93	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Merck & Co. Inc.	Buy	$260.9B	13.36%	21.26	19.23%
Eli Lilly And Company	Buy	$715.3B	567.78%	85.43	20.48%
Johnson & Johnson	Buy	$373.6B	10.92%	25.65	16.74%
Novo Nordisk A/s	Buy	$472.8B	280.83%	34.03	35.01%
Abbvie Inc	Buy	$323.5B	109.61%	63.74	9.22%

Merck & Co. Inc. Dividend announcements

Merck & Co. Inc. Dividends June, 2024
In the quarter ending June,2024. Merck & Co. Inc. has declared dividend of $0.81
Read More

About Merck & Co. Inc.

Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $297.5 Billion. It has a P.E ratio of 21.66. The shares of Merck & Co. Inc. are trading at $100.61. .

Organization	Merck & Co. Inc.
Employees	70000
CEO	Mr. Robert M. Davis J.D.
Industry	Health Technology

Important FAQs about investing in Merck & Co. Inc. from India :

What is Merck & Co. Inc. share price today?

Merck & Co. Inc. (MRK) share price today is $100.61.

Can Indians buy Merck & Co. Inc. shares?

Yes, Indians can invest in the Merck & Co. Inc. (MRK) from India.

With INDmoney, you can buy Merck & Co. Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Merck & Co. Inc. at zero transaction cost.

How can I buy Merck & Co. Inc. shares from India?

It is very easy to buy Merck & Co. Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Merck & Co. Inc. be purchased?

Yes, you can buy fractional shares of Merck & Co. Inc. with INDmoney app.

What are the documents required to start investing in Merck & Co. Inc. stocks?

To start investing in Merck & Co. Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.